0
Critical Care |

Extracorporeal Membrane Oxygenation in Obstructive Lung Diseases Refractory to Conventional Therapy

Tejaswini Kulkarni, MD; Krittika Teerapuncharoen, MD; Nirmal Sharma, MD; Keith Wille, MD; Enrique Diaz-Guzman, MD
Author and Funding Information

University of Alabama Birmingham, Birmingham, AL


Chest. 2015;148(4_MeetingAbstracts):323A. doi:10.1378/chest.2280697
Text Size: A A A
Published online

Abstract

SESSION TITLE: Novel Assessment and Treatments for Respiratory Failure

SESSION TYPE: Original Investigation Slide

PRESENTED ON: Tuesday, October 27, 2015 at 11:00 AM - 12:15 PM

PURPOSE: Approximately 7% of patients with status asthmaticus (SA) and 11% of patients with chronic obstructive pulmonary disease exacerbations (AECOPD) die each year despite maximal conventional therapy and mechanical ventilator (MV) support. The use of extracorporeal membrane oxygenation (ECMO) in patients with obstructive lung diseases is uncommon. Our objective was to review the characteristics and outcomes in patients on ECMO for SA and AECOPD in comparison to other causes of respiratory failure.

METHODS: We conducted a retrospective cohort study using the international Extracorporeal Life Support Organization registry and included all adult (≥18 years of age) cases between January 1988 and December 2014 in our analysis. Primary outcome was survival to hospital discharge. Student’s t-test was used to compare continuous variable and chi-squared statistic was used to compare categorical variables. Multivariable logistic regression was performed to determine the odds of survival on ECMO while adjusting for potential confounding.

RESULTS: 456 adult respiratory failure ECMO cases were reported to the ECLS registry and survival to hospital discharge was 61.6% for these patients. SA and AECOPD was the primary indication in 129 cases, they were younger (mean age 39.2 vs 50.4 years, p<0.0001) with no difference in gender (males 43.4% vs 49.54%, p=0.23) or race (Caucasian 60.47% vs 68.8%, p=0.09) when compared to patients on ECMO for other causes of respiratory failure. They were more acidotic at initiation of ECMO (7.10 vs 7.23, p=0.01) but had lower oxygen requirement (FiO2 0.81 vs 0.92, p<0.001) and shorter duration on ECMO (110.8 vs 184.9 days, p= 0.002). Veno-venous ECMO was used more frequently in patients with SA and AECOPD (82.35% vs 56.92%, p=0.0003). On multivariate analysis, patients with SA and AECOPD had a higher survival to hospital discharge (OR 1.98, CI 1.04 - 3.77,p=0.03) compared to patients on ECMO for other causes of respiratory failure, while adjusting for age, race, gender, oxygen requirement and hours of ECMO.

CONCLUSIONS: In conclusion, our review of the ELSO registry suggests that ECMO may be beneficial in adult patients with life-threatening SA and AECOPD refractory to maximal pharmacological therapy and MV. Further studies are needed to determine if ECMO use can reduce morbidity or mortality in these patients.

CLINICAL IMPLICATIONS: ECMO may be useful in patients with refractory SA or AECOPD on MV for providing adequate gas change and improving survival.

DISCLOSURE: The following authors have nothing to disclose: Tejaswini Kulkarni, Krittika Teerapuncharoen, Nirmal Sharma, Keith Wille, Enrique Diaz-Guzman

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Editor's Commentary. Respir Care 2016;61(1):i.
A Noteworthy Case of Acute Bronchitis. Ann Am Thorac Soc 2016;13(2):285-7.
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543